周四，Jefferies将ALX Oncology (NASDAQ:ALXO)的股票评级从"买入"下调至"持有"，并将目标价从12.00美元大幅下调至2.00美元。这一决定是在对公司最近的临床试验结果进行详细评估后做出的。 InvestingPro 数据显示，该公司股票今年以来已下跌87%，目前市值为9700万美元。

ALX Oncology (NASDAQ:ALXO) traded lower on Thursday after Jefferies downgraded the cancer drug developer to Hold from Buy, ...

周三，Stifel维持了对ALX Oncology（纳斯达克股票代码：ALXO）股票的持有评级，目标价保持在$3.00不变。这一决定是在ALX Oncology的evo与JAZZ Pharmaceuticals的zanidatamab联合治疗临床试验结果公布后做出的。该试验在HER2阳性转移性乳腺癌（HER2+ mBC）患者中显示出高响应率。

E nugu State has announced a groundbreaking partnership with ALX Nigeria aimed at providing essential Artificial Intelligence (AI) skills to 5,000 youths. This initiative, known as the Free ...

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has received an average rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Three investment ...

Investing.com -- Shares of Alx Oncology (NASDAQ: ALXO) fell in pre-market trading Thursday after Jefferies downgraded the ...

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for ...